Price (delayed)
$2.22
Market cap
$14.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.75
Enterprise value
-$5.68M
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in
Special dividends are included in TTM DPS and yield
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.